GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Genome & Co (XKRX:314130) » Definitions » Net Income From Continuing Operations

Genome (XKRX:314130) Net Income From Continuing Operations : ₩-25,261 Mil (TTM As of Mar. 2025)


View and export this data going back to 2018. Start your Free Trial

What is Genome Net Income From Continuing Operations?

Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. Genome's net income from continuing operations for the three months ended in Mar. 2025 was ₩-7,125 Mil. Its net income from continuing operations for the trailing twelve months (TTM) ended in Mar. 2025 was ₩-25,261 Mil.

Genome Net Income From Continuing Operations Historical Data

The historical data trend for Genome's Net Income From Continuing Operations can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Genome Net Income From Continuing Operations Chart

Genome Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Net Income From Continuing Operations
Get a 7-Day Free Trial -31,186.05 -36,003.58 -56,949.96 -50,652.86 -26,849.54

Genome Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Net Income From Continuing Operations Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -8,714.29 897.92 -7,210.34 -11,822.83 -7,125.32

Genome Net Income From Continuing Operations Calculation

Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. It excludes extraordinary items, income from the cumulative effects of accounting changes, non-recurring items, income from tax loss carry forward, and preferred dividends.

Net Income From Continuing Operations for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was ₩-25,261 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Genome Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Genome & Co (XKRX:314130) » Definitions » Net Income From Continuing Operations
Comparable Companies
XKRX:166480 XKRX:168330 XKRX:261780 XKRX:296160 XKRX:222110 XKRX:049960 XKRX:388870 XKRX:378800 XKRX:389030 XKRX:348150 VRTX ASX:CSL REGN XKRX:207940 ALNY XBRU:ARGX XBRU:UCB ONC XKRX:068270 BNTX
Traded in Other Exchanges
N/A
Address
Innovalley A-801, Pangyo-ro 253, Bundang-gu, Gyeonggi-do, Seongnam-si, KOR, 13486
Website
http://www.genomecom.co.kr
Genome & Co is a Korean company engaged in researching and developing dietary supplements, cosmeceuticals, and new drugs. Its products pipeline includes immunooncology therapeutic supplement for treatment of immuno-oncology, lung cancer, colorectal cancer, stomach cancer, breast cancer, pancreatic cancer; dietary supplements for treating obesity and diabetes; cosmetics used for acne and atopic dermatitis; and also produces In Virto fertilization medicine.

Genome Headlines

No Headlines